Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,970 total articles

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical to jointly commercialize two biosimilar candidates—AVT34 (biosimilar to Imfinzi®) and AVT87 (biosimilar to Hemlibra®)—in the United States and selected Asian markets. The deal includes semi-exclusive U.S. rights for both companies and exclusive rights…

MicroCloud Hologram Inc. Announces Acquisition of 140,268 MSTR Shares Through Structured Note Investment Product, Continuing Its Strategic Investment in Bitcoin-Related Assets

MicroCloud Hologram Inc. Announces Acquisition of 140,268 MSTR Shares Through Structured Note Investment Product, Continuing Its Strategic Investment in Bitcoin-Related Assets

MicroCloud Hologram Inc. announced the acquisition of 140,268 shares of MicroStrategy Incorporated (MSTR) common stock through the maturity and settlement of a structured note investment product worth approximately $15.76 million. The company views this as a strategic move to strengthen its position in Bitcoin and digital asset-related opportunitie…

Space-Eyes Announces Four Distinguished Appointments to Post-Combination Board of Directors Reflecting Deep National Security, Intelligence, Defense and Global Capital Markets Expertise

Space-Eyes Announces Four Distinguished Appointments to Post-Combination Board of Directors Reflecting Deep National Security, Intelligence, Defense and Global Capital Markets Expertise

Space-Eyes, an AI-driven geospatial intelligence and counter-UAS company, announced the appointments of four distinguished leaders to its post-combination board. These appointments bring deep expertise in national security, defense, strategy, aerospace manufacturing, and global finance as Space-Eyes prepares to become a publicly traded company on N…

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

Splash Beverage Group, trading on NYSE American as SBEV, is changing its name to Endovia Health Sciences, Inc. and adopting a new ticker symbol, EDVA, starting August 24, 2026. This rebranding reflects the company’s strategic transformation from beverage operations into a diversified cannabinoid-based health sciences platform. Endovia focuses on th…

Quantum X Labs Announces Additional Advancement in Quantum Error Correction Using NVIDIA CUDA-Q with New Results on Google’s Dataset

Quantum X Labs Announces Additional Advancement in Quantum Error Correction Using NVIDIA CUDA-Q with New Results on Google’s Dataset

Quantum X Labs announced enhanced performance of its AI-assisted quantum error-correction decoder using Google’s public surface-code dataset from real quantum hardware. The decoder, trained exclusively on synthetic data, outperformed benchmark algorithms, supporting the company’s progress toward reliable, scalable, and real-time quantum error corre…

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RenovoRx, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement after its stock price remained at or above $1.00 for 10 consecutive business days. This milestone follows the company's record quarterly revenue, expanded commercial uptake of its FDA-cleared RenovoCath drug-delivery device, and full enrollment in the Ph…

reAlpha (NASDAQ: AIRE) Completes InstaMortgage Acquisition, Adding Direct Lending Capabilities to Company’s Integrated Platform

reAlpha (NASDAQ: AIRE) Completes InstaMortgage Acquisition, Adding Direct Lending Capabilities to Company’s Integrated Platform

reAlpha Tech Corp. has completed its acquisition of InstaMortgage Inc., a multi-state mortgage lender. This acquisition integrates direct lending capabilities into reAlpha's platform, enabling the company to originate, underwrite, and fund mortgages in-house across 38 states and Washington, D.C. The move aims to create a seamless end-to-end homebuy…

Asure Expands Enterprise Payroll Tax and Treasury Solutions Via the 330,000-Customer AWS Marketplace

Asure Expands Enterprise Payroll Tax and Treasury Solutions Via the 330,000-Customer AWS Marketplace

Asure Software is launching its Enterprise Payroll Tax and Treasury solutions on the AWS Marketplace, gaining access to 330,000 AWS customers. This strategic move aims to expand Asure's addressable market by leveraging AWS's extensive enterprise ecosystem and streamlined procurement processes, potentially accelerating growth in one of its fastest-g…

Synergy CHC Corp. Announces Receipt of Nasdaq Letter

Synergy CHC Corp. Announces Receipt of Nasdaq Letter

Synergy CHC Corp. announced it received a Nasdaq notice for non-compliance due to the delayed filing of its Q2 Form 10-Q quarterly report. The company has until October 19, 2026, to submit a compliance plan to Nasdaq, and potentially until February 10, 2027, to regain compliance. There's uncertainty regarding the timing of the filing, which poses r…

LifeVantage Declares Quarterly Dividend

LifeVantage Declares Quarterly Dividend

LifeVantage Corporation declared a quarterly cash dividend of $0.05 per share, to be paid on September 15, 2026, signaling confidence in its financial health and providing returns to shareholders. The company, a leader in health and wellness products leveraging nutrigenomics, highlighted its diverse product lineup and reiterated caution regarding f…

Springbig Completes Reorganization, Eliminating Approximately $12.5 Million of Secured Debt and Positioning SBIG to Explore Strategic Alternatives

Springbig Completes Reorganization, Eliminating Approximately $12.5 Million of Secured Debt and Positioning SBIG to Explore Strategic Alternatives

SpringBig Holdings, Inc. has completed a reorganization that eliminated approximately $12.5 million in secured debt by transferring ownership of its former operating subsidiary to an entity designated by secured lenders. Now operating as a streamlined, debt-free public company, SpringBig is evaluating multiple strategic opportunities aimed at incre…

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Ambros Therapeutics and Werewolf Therapeutics have entered into an all-stock merger agreement to create a Nasdaq-listed late-stage biotech company focused on developing neridronate, a potential first FDA-approved treatment for Complex Regional Pain Syndrome Type 1 (CRPS-1). Concurrent with the merger, they secured $150 million in an oversubscribed …

GDEV announces results for the second quarter and first half of 2026

GDEV announces results for the second quarter and first half of 2026

GDEV Inc. announced its unaudited financial results for Q2 and first half of 2026, reporting a 22% revenue decrease in Q2 and 11% for H1 2026 compared to 2025, primarily due to lower bookings and paying users. Despite revenue declines, the company improved net profit and operating cash flows in both periods by reducing marketing expenses and optimi…

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Milestone Pharmaceuticals initiated the ReVeRA-301 Phase 3 trial to evaluate the safety and efficacy of etripamil nasal spray as a self-administered treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR). Building on FDA approval of etripamil for PSVT and promising Phase 2 results, the trial aims to reduce reliance on emergency ca…

Brandywine Realty Trust Announces Upsize and Extension of Expiration of the Previously Announced Tender Offer for the 2029 Notes

Brandywine Realty Trust Announces Upsize and Extension of Expiration of the Previously Announced Tender Offer for the 2029 Notes

Brandywine Realty Trust announced an increase in the aggregate principal amount it will accept in its cash tender offer for its 2029 Notes from $50 million to $70 million. The expiration date for the tender offer was extended from August 21 to August 25, 2026. Terms include a tender offer consideration of $1,068.75 per $1,000 principal amount tende…

Foresight Evaluates Expansion into New Technology Markets, Including AI-Based Technologies, Cybersecurity and Data Centers

Foresight Evaluates Expansion into New Technology Markets, Including AI-Based Technologies, Cybersecurity and Data Centers

Foresight Autonomous Holdings Ltd., an innovator in 3D perception systems and automotive safety technologies, announced it is evaluating opportunities to expand into new technology sectors including AI-based technologies, cybersecurity, and data centers. The company is considering possible acquisitions in these areas while continuing to develop its…

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Arbutus Biopharma Corporation plans to repurchase up to $230 million of its common shares via a modified Dutch Auction tender offer, reflecting proceeds from its recent settlement with Moderna. The offer will purchase shares at prices between $5.00 and $5.75 per share and is expected to be funded by the company's cash on hand. Arbutus continues to …

Meridian3 Industrials Acquisition Corp Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing August 24, 2026

Meridian3 Industrials Acquisition Corp Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing August 24, 2026

Meridian3 Industrials Acquisition Corp announced that beginning August 24, 2026, holders of units from its IPO may elect to trade Class A ordinary shares and warrants separately on the Nasdaq. The units will continue trading under the symbol MIACU, with separated Class A shares and warrants trading under MIAC and MIACW respectively. The company is …